Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KTX-201
- Development stage
- Preclinical
- Lead developer
- Kymera Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Intravenous, Intraperitoneal
01
Overview
KTX-201 is an investigational **STAT3-targeted protein degrader** from **Kymera Therapeutics** being developed for **immuno-oncology**. Formerly known as **KYM-003**, it is designed to selectively induce degradation of **signal transducer and activator of transcription 3**, a transcription factor that promotes tumor-associated immune suppression and tumor cell survival. By degrading STAT3 in both immune and tumor cells, KTX-201 is intended to reverse immunosuppressive gene-expression programs and enhance antitumor immunity. Preclinical data described activity in in vitro non-small cell lung cancer models and antitumor effects in immune checkpoint inhibitor-resistant mouse colorectal cancer models, supporting development in cancer settings characterized by immune suppression.
02
Targets
E3 ligase (E3 ubiquitin ligases)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on KTX-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KTX-201.